Douglas E. Dylla

439 total citations
21 papers, 317 citations indexed

About

Douglas E. Dylla is a scholar working on Hepatology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Douglas E. Dylla has authored 21 papers receiving a total of 317 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hepatology, 10 papers in Infectious Diseases and 10 papers in Epidemiology. Recurrent topics in Douglas E. Dylla's work include Hepatitis C virus research (16 papers), Liver Disease Diagnosis and Treatment (7 papers) and Viral gastroenteritis research and epidemiology (4 papers). Douglas E. Dylla is often cited by papers focused on Hepatitis C virus research (16 papers), Liver Disease Diagnosis and Treatment (7 papers) and Viral gastroenteritis research and epidemiology (4 papers). Douglas E. Dylla collaborates with scholars based in United States, Canada and Italy. Douglas E. Dylla's co-authors include Paul B. McCray, Patrick L. Sinn, Melissa A. Hickey, Scott A. Jeffers, Patrick D. Staber, David Avram Sanders, Beverly L. Davidson, Daniel E. Michele, Philip Ng and Terence R. Flotte and has published in prestigious journals such as Journal of the American College of Cardiology, Hepatology and Journal of Virology.

In The Last Decade

Douglas E. Dylla

20 papers receiving 314 citations

Peers

Countries citing papers authored by Douglas E. Dylla

Since Specialization

Citations

This map shows the geographic impact of Douglas E. Dylla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas E. Dylla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas E. Dylla more than expected).

Fields of papers citing papers by Douglas E. Dylla

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas E. Dylla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas E. Dylla. The network helps show where Douglas E. Dylla may publish in the future.

Co-authorship network of co-authors of Douglas E. Dylla

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas E. Dylla. A scholar is included among the top collaborators of Douglas E. Dylla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas E. Dylla. Douglas E. Dylla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Reported adverse events related to use of hepatitis C virus direct-acting antivirals with opioids: 2017–2021 2023 ·Harm Reduction Journal ·Anthony Martinez, (unknown), Douglas E. Dylla, John Marcinak, Michelle Collins, (unknown), Brian Conway	0
2	Shorter Duration Hepatitis C Virus Treatment is Associated with Better Persistence to Prescription Refills in People Who Inject Drugs: A Real-World Study 2023 ·Advances in Therapy ·Anthony Martinez, Wei‐Han Cheng, Steven E. Marx, Shivaji Manthena, Douglas E. Dylla, Lauren Wilson, Emmanuel Thomas	2
3	Assessment of Drug–Drug Interaction Risk Between Intravenous Fentanyl and the Glecaprevir/Pibrentasvir Combination Regimen in Hepatitis C Patients Using Physiologically Based Pharmacokinetic Modeling and Simulations 2023 ·Infectious Diseases and Therapy ·Dwaipayan Mukherjee, Michelle A. Collins, Douglas E. Dylla, Jatinder Kaur, Dimitri Semizarov, Anthony Martinez, Brian E. Conway, (unknown), Nael M. Mostafa	3
4	Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real‐world cohorts 2022 ·Journal of Viral Hepatitis ·Jordan J. Feld, Xavier Forns, Douglas E. Dylla, Hiromitsu Kumada, Victor de Lédinghen, Lai Wei, Robert S. Brown, Robert Flisiak, Pietro Lampertico, Dominique Thabut, (unknown), Fernando Tatsch, Margaret Burroughs, John Marcinak, Zhenzhen Zhang, Amanda Emmett, Ira M. Jacobson	3
5	Awareness and Epidemiology of Chronic Hepatitis C Virus Infections in Florida 2021 ·Infectious Diseases and Therapy ·Emmanuel Thomas, Wei‐Han Cheng, Douglas E. Dylla, Steven E. Marx, (unknown), Qingqing Xu	4
6	Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts 2021 ·Advances in Therapy ·Xavier Forns, Jordan J. Feld, Douglas E. Dylla, Stanislas Pol, Kazuaki Chayama, Jinlin Hou, Jeong Heo, Pietro Lampertico, Ashley Brown, (unknown), Fernando Tatsch, Margaret Burroughs, John Marcinak, Zhenzhen Zhang, Amanda Emmett, Stuart C. Gordon, Ira M. Jacobson	7
7	Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials 2021 ·Journal of Viral Hepatitis ·Edward Gane, Victor de Lédinghen, Douglas E. Dylla, Giuliano Rizzardini, Mitchell L. Shiffman, Stephen T. Barclay, José Luís Calleja, Zhenyi Xue, Margaret Burroughs, Julio Gutiérrez	16
8	Epidemiology and Clinical Characteristics of Individuals with Hepatitis C Virus Infection in the United States, 2017–2019 2021 ·Advances in Therapy ·Nancy Reau, Mark Sulkowski, Emmanuel Thomas, Vinay Sundaram, Qingqing Xu, Wei‐Han Cheng, Steven E. Marx, (unknown), Shivaji Manthena, Viktor Chirikov, Douglas E. Dylla, (unknown), (unknown), Sammy Saab	9
9	High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence 2021 ·The American Journal of Gastroenterology ·Philippe J. Zamor, Ashley Brown, Douglas E. Dylla, John Dillon, Anne F. Luetkemeyer, Jordan J. Feld, David Mutimer, Reem Ghalib, Eric D. Crown, Sandra Lovell, Yiran Hu, Christophe Moreno, David R. Nelson, Massimo Colombo, George Papatheodoridis, Juergen Rockstroh, Richard Skoien, Eric Lawitz, Ira M. Jacobson	8
10	Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection 2020 ·Advances in Therapy ·Steven L. Flamm, Jens Kort, Steven E. Marx, (unknown), Douglas E. Dylla, Bruce R. Bacon, Michael P. Curry, Naoky Tsai, (unknown)	14
11	Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection 2020 ·Clinical Gastroenterology and Hepatology ·Eli Zuckerman, Julio Gutiérrez, Douglas E. Dylla, Victor de Lédinghen, Andrew J. Muir, Michael Gschwantler, Massimo Puoti, Florin Alexandru Căruntu, Jihad Slim, Frederik Nevens, Samuel H. Sigal, Stanley M. Cohen, Linda Fredrick, (unknown), Lino Rodrigues, John Dillon	15
12	OUTCOMES OF PATIENTS INTERRUPTING GLECAPREVIR/PIBRENTASVIR TREATMENT: A CASE SERIES FROM CLINICAL TRIALS 2019 ·Hepatology ·Philippe J. Zamor, John Dillon, Douglas E. Dylla, David Mutimer, Reem Ghalib, Massimo Colombo, Richard Skoien, Eric D. Crown, Yiran Hu, Eric Lawitz	2
13	SAFETY AND EFFICACY OF STATIN MANAGEMENT DURING GLECAPREVIR/PIBRENTASVIR TREATMENT FOR CHRONIC HEPATITIS C 2018 ·Journal of the American College of Cardiology ·Paul Y. Kwo, Peter J.H. Jones, (unknown), Joseph Gathe, Yao Yu, Douglas E. Dylla, Ariel Porcalla, Federico Mensa, Peter P. Tóth	1
14	Time to viral suppression does not impact SVR in patients treated with Glecaprevir/Pibrentasvir for 8 weeks 2018 ·Journal of Hepatology ·C. Sarrazin, Thuy B. Tran, Douglas E. Dylla, (unknown), Satyam Arora, (unknown), Yunzhang Hu, (unknown), Federico Mensa, David Wyles	1
15	Sustained Virologic Response Predicts Fibrosis Regression Measured by Fibrotest in HCV-Infected Patients 2016 ·Journal of Hepatology ·Xavier Forns, Tania M. Welzel, E. Cohen, Ira M. Jacobson, Mitchell Davis, Robert Reindollar, Yang Hu, Douglas E. Dylla, Jeffrey Enejosa, Roger Trinh, Mark Sulkowski	1
16	Lentiviral Vector Gene Transfer to Porcine Airways 2012 ·Molecular Therapy — Nucleic Acids ·Patrick L. Sinn, Ashley L. Cooney, (unknown), Douglas E. Dylla, Tanner J. Wallen, Alejandro A. Pezzulo, Eugene H. Chang, Paul B. McCray	41
17	Altering α-dystroglycan receptor affinity of LCMV pseudotyped lentivirus yields unique cell and tissue tropism 2011 ·PubMed ·Douglas E. Dylla, Litao Xie, Daniel E. Michele, Stefan Kunz, Paul B. McCray	15
18	Basolateral Entry and Release of New and Old World Arenaviruses from Human Airway Epithelia 2008 ·Journal of Virology ·Douglas E. Dylla, Daniel E. Michele, Kevin P. Campbell, Paul B. McCray	24
19	Viral Vector–mediated and Cell-based Therapies for Treatment of Cystic Fibrosis 2007 ·Molecular Therapy ·Terence R. Flotte, Philip Ng, Douglas E. Dylla, Paul B. McCray, Guoshun Wang, Jay K. Kolls, Jim Hu	54
20	Lentivirus Vectors Pseudotyped with Filoviral Envelope Glycoproteins Transduce Airway Epithelia from the Apical Surface Independently of Folate Receptor Alpha 2003 ·Journal of Virology ·Patrick L. Sinn, Melissa A. Hickey, Patrick D. Staber, Douglas E. Dylla, Scott A. Jeffers, Beverly L. Davidson, David Avram Sanders, Paul B. McCray	96

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact